Page 123 - 南京医科大学自然版

第44卷第7期 杨 澜，吉宁飞，黄 茂. 肺肉瘤样癌免疫治疗新进展［J］.
2024年7月 南京医科大学学报（自然科学版），2024，44（7）：1002-1009 ·1007 ·

［11］YANG J，ANTIN P，BERX G，et al. Guidelines and defini⁃ is regulated via microRNA ⁃ 200/ZEB1 axis control of
tions for research on epithelial⁃mesenchymal transition［J］. tumour cell PD⁃L1 expression and intratumoral immuno⁃
Nat Rev Mol Cell Biol，2020，21（6）：341-352 suppression［J］. Nat Commun，2014，5：5241
［12］NURMAGAMBETOVA A，MUSTYATSA V，SAIDOVA A， ［25］BURGER G A，NESENBEREND D N，LEMS C M，et al.
et al. Morphological and cytoskeleton changes in cells Bidirectional crosstalk between epithelial ⁃ mesenchymal
after EMT［J］. Sci Rep，2023，13（1）：22164 plasticity and IFN⁃γ⁃induced PD⁃L1 expression promotes
［13］PEGLION F，ETIENNE ⁃ MANNEVILLE S. Cell polarity tumour progression［J］. R Soc Open Sci，2022，9（11）：
changes in cancer initiation and progression［J］. J Cell Biol， 220186
2024，223（1）：e202308069 ［26］WANG G，XU D，ZHANG Z，et al. The pan⁃cancer land⁃
［14］BERR A L，WIESE K，DOS S G，et al. Vimentin is scape of crosstalk between epithelial⁃mesenchymal transi⁃
required for tumor progression and metastasis in a mouse tion and immune evasion relevant to prognosis and immu⁃
model of non⁃small cell lung cancer［J］. Oncogene，2023， notherapy response［J］. NPJ Precis Oncol，2021，5（1）：56
42（25）：2074-2087 ［27］JIANG Y，ZHAN H. Communication between EMT and
［15］NAM M W，KIM C W，CHOI K C. Epithelial⁃mesenchy⁃ PD⁃L1 signaling：new insights into tumor immune eva⁃
mal transition ⁃ inducing factors involved in the progres⁃ sion［J］. Cancer Lett，2020，468：72-81
sion of lung cancers［J］. Biomol Ther（Seoul），2022，30 ［28］LI X，CHEN L，PENG X，et al. Progress of tumor⁃associat⁃
（3）：213-220 ed macrophages in the epithelial⁃mesenchymal transition
［16］PÉREZ⁃GONZÁLEZ A，BÉVANT K，BLANPAIN C. Can⁃ of tumor［J］. Front Oncol，2022，12：911410
cer cell plasticity during tumor progression，metastasis ［29］SEZER A，KILICKAP S，GÜMÜŞ M，et al. Cemiplimab
and response to therapy［J］. Nat Cancer，2023，4（8）： monotherapy for first ⁃ line treatment of advanced non ⁃
1063-1082 small⁃cell lung cancer with PD⁃L1 of at least 50%：a mul⁃
［17］GUO Y，JI X，LIU J，et al. Effects of exosomes on pre⁃met⁃ ticentre ，open ⁃ label ，global ，phase 3 ，randomised ，
astatic niche formation in tumors［J］. Mol Cancer，2019， controlled trial［J］. Lancet，2021，397（10274）：592-604
18（1）：39 ［30］ MOK T，WU Y L，KUDABA I，et al. Pembrolizumab
［18］STEPHAN⁃FALKENAU S，STREUBEL A，MAIRINGER versus chemotherapy for previously untreated，PD⁃L1⁃
T，et al. Integrated clinical，molecular and immunological expressing，locally advanced or metastatic non⁃small⁃cell
characterization of pulmonary sarcomatoid carcinomas lung cancer（KEYNOTE⁃042）：a randomised，open⁃label，
reveals an immune escape mechanism that may influence controlled，phase 3 trial［J］. Lancet，2019，393（10183）：
therapeutic strategies［J］. Int J Mol Sci，2023，24（13）： 1819-1830
10558 ［31］ETTINGER D S，WOOD D E，AISNER D L，et al. Non⁃
［19］ZHANG Y C，ZHANG Y T，WANG Y，et al. What role small cell lung cancer，version 3.2022，NCCN clinical
does PDL1 play in EMT changes in tumors and fibrosis?［J］. practice guidelines in oncology［J］. J Natl Compr Canc
Front Immunol，2023，14：1226038 Netw，2022，20（5）：497-530
［20］KOH Y W，HAN J H，HAAM S. Expression of PD⁃L1， ［32］ ZHOU F，GUO H，ZHOU X，et al. Immune checkpoint
cancer stem cell and epithelial ⁃ mesenchymal transition inhibitors plus chemotherapy in patients with locally
phenotype in non⁃small cell lung cancer［J］. Pathology， advanced or metastatic pulmonary sarcomatoid carcinoma：

2021，53（2）：239-246 a multicentric real⁃world study［J］. Ther Adv Med Oncol，
［21］LI F，ZHU T，YUE Y，et al. Preliminary mechanisms of 2022，14：7418505
regulating PD⁃L1 expression in non⁃small cell lung cancer ［33］QIAN X，WANG Y，LIU F，et al. The efficacy and safety
during the EMT process［J］. Oncol Rep，2018，40（2）： analysis of first ⁃ line immune checkpoint inhibitors in
775-782 pulmonary sarcomatoid carcinoma［J］. Front Immunol，
［22］ASGAROVA A，ASGAROV K，GODET Y，et al. PD⁃L1 2022，13：956982
expression is regulated by both DNA methylation and ［34］DE CASTRO G J，KUDABA I，WU Y L，et al. Five⁃year
NF⁃κB during EMT signaling in non⁃small cell lung carci⁃ outcomes with pembrolizumab versus chemotherapy as
noma［J］. Oncoimmunology，2018，7（5）：e1423170 first ⁃ line therapy in patients with non ⁃ small ⁃ cell lung
［23］HSU J M，XIA W，HSU Y H，et al. STT3⁃dependent PD⁃L1 cancer and programmed death ligand⁃1 tumor proportion
accumulation on cancer stem cells promotes immune eva⁃ score≥1% in the KEYNOTE⁃042 study［J］. J Clin Oncol，
sion［J］. Nat Commun，2018，9（1）：1908 2023，41（11）：1986-1991
［24］CHEN L，GIBBONS D L，GOSWAMI S，et al. Metastasis ［35］TOYOZAWA R，ITAHASHI K，GOTO Y，et al. 1292P